Last updated: 11/03/2018 21:14:38
This product has been transferred to Novartis. GSK Clinical Study Register is no longer maintained for this study.

Dabrafenib-Trametinib Combination Metastatic Melanoma Named Patient Programme Retrospective Chart Review (DESCRIBE II)DESCRIBE

GSK study ID
201088
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
No longer a GSK study
No longer a GSK study
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Dabrafenib-Trametinib Combination Metastatic Melanoma Named Patient Programme Retrospective Chart Review (DESCRIBE II)
Trial description: Rationale: The purpose of this study is to understand the clinical outcomes and treatment patterns in patients who participated in the Named Patient Programme for dabrafenib + trametinib in metastatic melanoma.
Objectives:
Primary Objectives
Describe treatment patterns including systemic therapy, surgery, radiotherapy and any other interventions/procedures for patients with unresectable or metastatic melanoma who received dabrafenib + trametinib monotherapy as compassionate use.
Describe dabrafenib + trametinib treatment duration.
Secondary Objectives
Describe serious adverse events (SAEs) and AEs of special interest (AESI) during treatment with dabrafenib + trametinib.
Determine best overall response (OR) for dabrafenib + trametinib.
Determine progression-free survival (PFS) and overall survival (OS).
Describe patterns of progression by location (brain, visceral and non-visceral) and by type of progression (tumour growth, new lesion(s) and clinical progression).
Data Source/Study Design: Data will be collected via retrospective review of patient medical records.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Treatment patterns for patients with metastatic melanoma who received dabrafenib/trametinib as compassionate use

Timeframe: From intiation of first therapy to the last therapy recorded in the medical notesd

Dabrafenib/trametinib treatment duration

Timeframe: From initiation to termination of dabrafenib/trametinib therapy

Secondary outcomes:

Overall survival (OS) for dabrafenib/trametinib

Timeframe: From initiation of dabrafenib until death

Serious adverse events (SAEs) and AEs of special interest (AESI) during treatment with dabrafenib/trametinib

Timeframe: From initiation of dabrafenib until 28 days post dabrafenib termination

Type of progression (tumour growth, new lesion(s) and clinical progression)

Timeframe: At time of progression

Location of disease progression (brain, visceral and non-visceral)

Timeframe: At time of progression

Progression free survival (PFS) for dabrafenib/trametinib

Timeframe: From initiation of dabrafenib until progression

Best overall response (OR) for dabrafenib/trametinib

Timeframe: From initiation to termination of dabrafenib

Interventions:
  • Drug: Dabrafenib/Trametinib
    • Enrollment:
    1
    Primary completion date:
    Not applicable
    Observational study model:
    Cohort
    Time perspective:
    Retrospective
    Clinical publications:
    Not applicable
    Medical condition
    Melanoma
    Product
    dabrafenib, dabrafenib/trametinib, trametinib
    Collaborators
    Not applicable
    Study date(s)
    April 2014 to October 2015
    Type
    Observational
    Phase
    4

    Participation criteria

    Sex
    Female & Male
    Age
    18+ years
    Accepts healthy volunteers
    none
    • Patient received at least one dose of dabrafenib and one dose of trametinib as part of the Named Patient Programme at one of the participating study sites during the eligibility period (between 21 March 2013 to 31 January 2014)
    • Patient was 18 years of age or older at the time of enrolment into the Named Patient Programme
    • Medical chart is missing, empty, or not retrievable
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Patient received at least one dose of dabrafenib and one dose of trametinib as part of the Named Patient Programme at one of the participating study sites during the eligibility period (between 21 March 2013 to 31 January 2014)
    • Patient was 18 years of age or older at the time of enrolment into the Named Patient Programme
    Exclusion criteria:
    • Medical chart is missing, empty, or not retrievable

    Trial location(s)

    This study does not involve prospective enrollment of participants.

    Study documents

    No study documents available.

    Results overview

    No study documents available

    Recruitment status
    No longer a GSK study
    Actual primary completion date
    Not applicable
    Actual study completion date
    2015-23-10

    Plain language summaries

    Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

    Additional information about the trial

    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website